News & Events
Upcoming Events
MitoCon 2024
We are looking forward to the 14th edition of the Italian Conference on Mitochondrial Diseases, which focuses on the state of scientific research in Italy, as well as the advances, challenges, and opportunities in the field of mitochondrial medicine, both nationally and internationally.
October 25-27, 2024
Padua, Italy
AussieMit 2024
We are proud to support the 8th biennial AussieMit conference, which celebrates excellence in mitochondrial disease research.
November 26-29, 2024
Melbourne, Australia
CHOP Next Gen Panel
Our own Chad Glasser, Sr. Director, Clinical Research, will be participating in a discussion on the importance of outcome measure validation, natural history studies, and other approaches in deepening our understanding of primary mitochondrial disease.
September 20, 2024 | 10am-noon ET
Virtual
Press Releases
Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinical Development Program
Tisento Therapeutics, a privately held, clinical-stage biotechnology company developing novel medicines for diseases with significant unmet medical needs, today announced the initiation of a patient interview study to identify and describe the signs, symptoms, and health-related quality-of-life impacts of MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) that are most burdensome to adults and adolescents living with this rare mitochondrial disease. The interviews will inform the selection of clinical outcomes assessments and endpoint strategy for the company’s planned Phase 2b study of its investigational medicine, zagociguat, in MELAS.
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
It all begins with an idea.